Welcome to our dedicated page for Cingulate SEC filings (Ticker: CINGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cingulate’s SEC filings aren’t just numbers—they map the path from Precision Timed Release™ research to potential FDA approval. Yet dissecting a biotech 10-K that details trial design, cash burn, and warrant (CINGW) dilution can take hours. Stock Titan’s AI-powered analysis translates the scientific jargon and risk factors into concise takeaways, so you can focus on what matters.
Need to track Cingulate insider trading Form 4 transactions before the next data read-out? Our platform streams Cingulate Form 4 insider transactions real-time, flags option exercises, and links every trade to pipeline milestones. If you are asking, “Where’s the Cingulate quarterly earnings report 10-Q filing?” or want a Cingulate annual report 10-K simplified summary, the documents appear here the moment EDGAR posts—complete with AI highlights of R&D spend and PTR patent updates. We also answer common searches like “Cingulate SEC filings explained simply” and “understanding Cingulate SEC documents with AI.”
Each filing type unlocks a different angle: 8-Ks reveal dosing-study results—see “Cingulate 8-K material events explained.” Proxy statements unpack board expertise and Cingulate proxy statement executive compensation. Our earnings tools provide Cingulate earnings report filing analysis to spot cash-runway changes quarter over quarter. In one dashboard you can:
- Receive AI-generated summaries of 10-K, 10-Q, 8-K and S-1 documents
- Monitor Cingulate executive stock transactions Form 4
- Export red-lined comparisons across reporting periods
Director Jeffrey S. Ervin of Cingulate has been granted 15,000 stock options on June 20, 2025. The options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at the earlier of:
- One-year anniversary of grant date
- Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing represents a standard director compensation grant, with the options providing Ervin the right to purchase common stock at the specified strike price. The grant aligns the director's interests with shareholders through long-term equity incentives.
FAQ
What is the current stock price of Cingulate (CINGW)?
